Dashboard
Portfolios
Watchlist
Community
Discover
Screener
Community
/
United States
/
Pharmaceuticals & Biotech
/
CareDx
CDNA
CareDx
New Medicare Policies Will Erode Margins Despite Digital Gains
AN
AnalystLowTarget
Not Invested
Consensus Narrative from 5 Analysts
Published
07 Aug 25
Updated
16 Aug 25
0
Set Fair Value
0
votes
Share
AnalystLowTarget
's Fair Value
US$14.00
7.4% undervalued
intrinsic discount
16 Aug
US$12.97
Loading
1Y
-59.3%
7D
9.5%
Author's Valuation
US$14.0
7.4% undervalued
intrinsic discount
AnalystLowTarget Fair Value
View Valuation
Narrative
Updates
0
Valuator
Company Info
Notes
AnalystLowTarget Fair Value
US$14.0
7.4% undervalued
intrinsic discount
Future estimation in
3 Years
time period
Past
Future
-166m
483m
2014
2017
2020
2023
2025
2026
2028
Revenue US$483.4m
Earnings US$7.8m
Revenue
Profit Margin
Future PE
Revenue
% p.a.
0
Decrease
Increase
Current revenue growth rate
12.49%
Biotech revenue growth rate
11.95%
Other Inputs & Calculation
Risk Level (Discount Rate)
Our default considers factors like the company's size, volatility, profitablity and country of operation.
Risk Level (Discount Rate)
%
0
Decrease
Increase
Current discount rate
6.78%
Calculation
US$7.76m
Earnings '28
x
118.64x
PE Ratio '28
=
US$920.33m
Market Cap '28
US$920.33m
Market Cap '28
/
54.71m
No. shares '28
=
US$16.82
Share Price '28
US$16.82
Share Price '28
Discounted to 2025 @ 6.78% p.a.
=
US$13.82
Fair Value '25
